Solventum Corporation SOLV
Healthcare · Medical Instruments & Supplies · United States · S&P 500
Based on the available data, Solventum Corporation gets an algorithmic score of 54/100. It trades at 89.32 $, with a bullish technical trend (RSI 53.0) and 29.6% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (34.0%): generates strong profit on equity.
Weaknesses
- Negative free cash flow.
Fundamentals
| P/E | 10.95 |
| Forward P/E | 12.35 |
| PEG | 1.22 |
| P/B | 3.17 |
| EV/EBITDA | 17.64 |
| P/S | 1.83 |
| ROE % | 33.96 |
| ROA % | 2.70 |
| Gross margin % | 54.78 |
| Operating margin % | 9.78 |
| Net margin % | 17.26 |
| Revenue growth % (y/y) | 2.20 |
| Earnings growth % (y/y) | 3.90 |
| Revenue CAGR % | 0.79 |
| Earnings CAGR % | 5.03 |
| Debt/Equity % | 110.31 |
| Current ratio | 1.02 |
| FCF yield % | -0.07 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | -2.0 % |
| 3 months | +15.8 % |
| 6 months | +40.8 % |
| YTD | +13.0 % |
| 1 year | +25.1 % |
Risk
| 1-year volatility | 29.6 % |
| Beta | 0.78 |
| 5-year max drawdown | -40.0 % |
| Sharpe 1A | 0.77 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.